关于回购注销部分限制性股票通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 股票代码：000999 股票简称：华润三九 编号：2025—069 华润三九医药股份有限公司 债权申报所需材料包括：公司债权人可持证明债权债务关系存在的合同、协议及其他凭 证的原件及复印件到公司申报债权。 债权人为法人的，需同时携带法人营业执照副本原件及复印件、法定代表人身份证明文 件；委托他人申报的，除上述文件外，还需携带法定代表人授权委托书和代理人有效身份证 的原件及复印件。 债权人为自然人的，需同时携带有效身份证的原件及复印件；委托他人申报的，除上述 文件外，还需携带授权委托书和代理人有效身份证件的原件及复印件。 债权申报具体方式如下： 一、通知债权人的原由 华润三九医药股份有限公司（以下简称"华润三九"或"公司"）于 2025 年 9 月 1 日召 开 2025 年第五次临时股东会，审议通过《关于 2021 年限制性股票激励计划回购注销部分限 制性股票的议案》。根据《上市公司股权激励管理办法》《公司 2021 年限制性股票激励计划 （2022 年 12 月修订稿 ...

上海市锦天城（深圳）律师事务所 华润三九医药股份有限公司 2025 年第五次临时股东会 之 关于 法律意见书 上海市锦天城（深圳）律师事务所 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21、22、23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司 2025 年第五次临时股东会的 法律意见书 致：华润三九医药股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受华润三九医药 股份有限公司（以下简称"公司"）委托，就公司召开 2025 年第五次临时股东 会的有关事宜，根据《中华人民共和◿公司法》（以下简称"《公司法》"）、《上 市公司股东会规则》等有关法律、法规、规章和其他规范性文件以及《华润三九 医药股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具本法律 意见书。 为出具本法律意见书，本所律师对本次股东会所涉及的相关事项进行了必要 的核查和验证，审查了本所律师认为出具本法律意见书所需审查的相关文件、资 料，并现场参加了公司本次股东会的全过程。 在本法律意见书中，本所律师仅对本次股东会的 ...

股票代码：000999 股票简称：华润三九 编号：2025—068 华润三九医药股份有限公司 2025 年第五次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1、本次股东会无否决议案。 2、本次股东会不涉及变更前次股东会已通过的决议。 一、会议召开和出席情况 1、华润三九医药股份有限公司 2025 年第五次临时股东会采用现场投票和网络投票相结 合的方式召开。现场会议于 2025 年 9 月 1 日下午 14:30 在华润三九医药工业园综合办公中 心 105 会议室召开。同时，本次股东会通过深圳证券交易所交易系统投票的时间为 2025 年 9 月 1 日上午 9:15—9:25、9:30—11:30，下午 13:00-15:00；通过深圳证券交易所互联网 投票系统投票的时间为 2025 年 9 月 1 日 9：15 至 15:00 期间的任意时间。 2、出席本次股东会的股东情况如下： | 出席会议的股东及股东授权委托代表人数 | 1,185 | | --- | --- | | 代表股份数（股） | 1,099,672,584 | ...

Core Viewpoint - The Chinese medicine industry is experiencing significant performance divergence in the first half of 2025, with leading companies facing growth challenges despite favorable policies and accelerated approvals for innovative drugs [2][7]. Group 1: Performance of Leading Companies - Pizhou's performance in the first half of 2025 shows a sharp decline, with revenue of 5.379 billion yuan, down 4.81% year-on-year, and a net profit of 1.442 billion yuan, down 16.22%, marking the first decline in both metrics in nearly 11 years [2][3]. - China Resources Sanjiu reported a slight revenue increase of 4.99% but a significant net profit drop of 24.31%, highlighting internal operational challenges [4][5]. - Yiling Pharmaceutical's net profit increased by 26.03%, but this growth is questioned due to previous inventory issues and reliance on the "Lianhua" product series [6][7]. Group 2: Challenges and Strategic Responses - Pizhou's reliance on its core product for revenue has led to vulnerabilities, with sales in its liver disease segment down over 8% due to tightened insurance policies and reduced market demand [3][7]. - China Resources Sanjiu's recent acquisitions have not yielded the expected synergies, with the acquired Kunming Pharmaceutical Group experiencing a revenue decline of 11.68% and a net profit drop of 26.88% [4][5]. - Yiling Pharmaceutical's growth is largely based on a low comparison base from the previous year, and its core products are facing declining sales due to increased competition and reduced demand post-COVID-19 [6][7]. Group 3: Industry Trends and Future Outlook - The industry is witnessing a clash between old business models and new market demands, with a need for companies to move away from dependence on single products and focus on innovation [7][8]. - Despite having cash flow advantages, leading companies are not effectively converting these resources into innovation, leading to a situation where larger scale results in thinner profits [8]. - The performance struggles in the first half of 2025 may act as a catalyst for transformation in the Chinese medicine industry, emphasizing the importance of diversifying product offerings and enhancing R&D investments [8].

Market Overview - The Chinese traditional medicine sector saw a slight increase of 0.32% on August 29, with Darentang leading the gains [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Performers - Darentang (600329) closed at 46.11, with a rise of 4.80% and a trading volume of 167,100 shares, amounting to a transaction value of 765 million [1] - Enwei Pharmaceutical (301331) increased by 2.22% to close at 35.94, with a trading volume of 15,900 shares [1] - Jianmin Group (600976) rose by 2.19% to 42.43, with a transaction value of 208 million [1] Underperformers - Qidi Pharmaceutical (000590) decreased by 3.11% to 11.84, with a trading volume of 129,400 shares and a transaction value of 155 million [2] - Tianmu Pharmaceutical (600671) fell by 2.89% to 19.81, with a transaction value of 209 million [2] - Buchang Pharmaceutical (603858) saw a decline of 2.55% to 19.51, with a trading volume of 198,400 shares [2] Capital Flow - The traditional medicine sector experienced a net outflow of 510 million from institutional investors, while retail investors saw a net inflow of 469 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Darentang had a net inflow of 77.24 million from institutional investors, but a net outflow of 59.46 million from retail investors [3] - Yunnan Baiyao (000538) saw a net inflow of 55.91 million from institutional investors, while retail investors had a net outflow of 0.83 million [3] - Zhendong Pharmaceutical (300158) experienced a net inflow of 48.61 million from institutional investors, but a significant net outflow of 79.17 million from retail investors [3]

Group 1 - The core point of the article is that China Resources Sanjiu (000999) will have 640,100 restricted shares released on August 29, which accounts for 0.04% of the company's total share capital [1] - In the past year, a total of 3,685,900 shares have been released, representing 0.22% of the total share capital [1] - After this release, there will still be 6,894,300 restricted shares remaining, which is 0.41% of the total share capital [1] Group 2 - The details of the shareholders involved in the release include 640,100 shares from other incentive objects, with a market value of approximately 19.701 million yuan, and a lock-up period of 36 months [2] - The financial data for China Resources Sanjiu shows that for the first half of 2025, the main revenue was 14.81 billion yuan, an increase of 4.99% year-on-year, while the net profit attributable to shareholders decreased by 24.31% to 1.815 billion yuan [3] - The second quarter of 2025 saw a main revenue of 7.957 billion yuan, a year-on-year increase of 16.8%, but the net profit attributable to shareholders fell by 47.3% to 545 million yuan [3]

Group 1: Market Trends and Company Strategy - The retail market is expected to gradually rise in the long term, despite short-term challenges due to changes in retail channels and market conditions [3] - The company maintains a good partnership with commercial channels and chain pharmacies, actively supporting their transformation [3] - The company is focusing on the CHC health consumer goods sector, driven by health demand and technological innovation [3] Group 2: Inventory and Online Business Development - The overall channel inventory level for the CHC business is approximately 3 months, indicating a healthy state [4] - The company has achieved its online business target of 10% during the "14th Five-Year Plan" period and is planning further digital strategies for the "15th Five-Year Plan" [5] Group 3: Product Development and R&D Focus - The company is expanding its respiratory product line, including various formulations like 999 cold medicine and others, with no changes to the annual growth target [6][7] - R&D efforts are concentrated on innovative drugs, improved versions of existing drugs, and classic traditional Chinese medicine, with a focus on clinical value [8] - The company aims to enhance its independent R&D capabilities and pipeline vitality in the next strategic cycle [8] Group 4: Future Company Positioning and Incentives - Future positioning includes focusing on CHC for Huaren Sanjiu, prescription drugs for Tianshili, and premium traditional Chinese medicine for Kunyu Group [9] - The company plans to introduce a second phase of the stock incentive plan, following the success of the first phase launched in 2021 [11] - The company aims to distribute a cash dividend of 4.5 yuan per 10 shares, with an estimated total cash dividend of approximately 750 million yuan [12]

Core Viewpoint - Kunming Pharmaceutical Group aims to become a leader in the silver-haired health industry, marking a new entrepreneurial journey after being acquired by China Resources Sanjiu [1][2]. Group 1: Integration and Transformation - Following the acquisition, Kunming Pharmaceutical Group is undergoing a systematic restructuring, focusing on value, business, organization, and spirit over a three-year integration period [2]. - The company is transitioning its operational model from "experience-driven" to "data-driven" by leveraging digital tools developed with the support of China Resources Sanjiu [2][3]. - A significant channel reform is underway to consolidate its previously fragmented sales network, establishing a more centralized channel structure [3]. Group 2: Focus on Silver-Haired Health - The new management has prioritized focusing resources on the silver-haired health sector, moving away from previous scattered investments [4]. - The company has a strong foundation in natural medicine research, particularly in chronic disease management and elderly health [5]. - Kunming Pharmaceutical Group is implementing a dual-platform strategy focusing on chronic disease management and premium traditional Chinese medicine [5]. Group 3: Innovative Business Model - The company is developing a three-in-one model that combines pharmaceuticals, medical services, and emotional value, aiming to create a comprehensive health management ecosystem [6]. - Plans include the development of intelligent companionship devices that integrate medical data and AI to support elderly care [6]. Group 4: International Expansion - Kunming Pharmaceutical Group is actively pursuing international markets, particularly in traditional Chinese medicine, with a focus on plant-based medicines like Artemisinin and Sanqi [7]. - The company has submitted 90 overseas registration applications and has successfully registered 7 products, with its blood stasis remedy approved in 15 countries [7]. - The company aims to leverage its global network and expertise in Artemisinin to become a comprehensive international healthcare service provider [8].

Core Viewpoint - Kunming Pharmaceutical Group aims to become a leader in the silver-haired health industry, marking a new entrepreneurial journey after being acquired by China Resources Sanjiu [1][3] Group 1: Strategic Transformation - The company is undergoing a strategic transformation described as a "second entrepreneurship," focusing on a dual-driven approach of "integration + reform" [1][3] - A clear roadmap for integration has been established, with a three-year integration period to complete value, business, organization, and spirit restructuring [1][2] - The company is currently in a critical phase of "model reconstruction and deep channel transformation" [1] Group 2: Digitalization and Channel Integration - Kunming Pharmaceutical Group is leveraging China Resources Sanjiu's digital capabilities to shift its operational model from "experience-driven" to "data-driven" [2] - The company is reforming its sales channel system by integrating a previously fragmented network of distributors, establishing a more centralized channel structure [2] - The new channel system will focus resources on national brand building, laying a foundation for long-term development [2] Group 3: Research and Development Collaboration - The company is collaborating with multiple research institutions in the silver-haired health sector, combining strengths in resource integration and AI-assisted drug screening [2][3] - Joint research projects in traditional Chinese medicine are being explored, particularly in the field of specialty plant medicines [2] Group 4: Focus on Silver-Haired Health - The management has identified a need for greater focus in strategic planning, concentrating resources on the silver-haired health sector [3] - The company aims to leverage its historical expertise in natural medicine to enhance its offerings in chronic disease management and elderly health [3] Group 5: Innovative Business Model - An innovative business model combining "medicines + medical services + emotional value" is being developed to address the needs of the elderly [4] - The company plans to transition from a traditional pharmaceutical enterprise to a health management service provider, enhancing its research and digital capabilities [4] Group 6: International Expansion of Traditional Chinese Medicine - Kunming Pharmaceutical Group is actively pursuing international markets for traditional Chinese medicine, with a focus on plant-based medicines like artemisinin and Sanqi [5] - The company has submitted 90 overseas registration applications and successfully registered 7 products, with its blood stasis remedy approved in 15 countries [5] - The company aims to become a comprehensive international healthcare service provider, leveraging its global network and expertise in artemisinin products [5]

Core Insights - The company reported a revenue of 4.288 billion yuan for the first half of 2025, a year-on-year decline of 1.91% [1] - The pharmaceutical manufacturing and commercial sectors both experienced significant downturns, with manufacturing revenue slightly decreasing by 0.45% to 3.879 billion yuan and commercial revenue plummeting by 14.88% [1] - Despite the revenue decline, the net profit attributable to shareholders increased by 16.97% to 775 million yuan, largely due to non-recurring gains of 135 million yuan [1][2] - The core product, Dan Shen Drop Pill, saw a revenue decline of 2.98% in the cardiovascular and metabolic sector, contributing to the overall performance issues [1] Financial Performance - Non-recurring gains of 135 million yuan were primarily from non-current asset disposals, government subsidies, and changes in the fair value of financial assets, masking the weakness in core business operations [2] - The gross margin for the pharmaceutical manufacturing sector decreased by 0.7 percentage points, leading to an overall gross margin drop to 67.54%, indicating challenges in cost control and product competitiveness [2] - Operating cash flow net amount fell by 10.95% to 790 million yuan, while accounts receivable surged by 46.86% to 1.169 billion yuan, increasing the proportion of receivables to 27.26% of revenue, highlighting rising collection pressures and potential bad debt risks [2] Management Changes and Strategic Outlook - Following the change in control, the management team underwent significant restructuring, with the founder's son stepping down as chairman and nearly ten core executives leaving the company [3] - The integration process under the new ownership by China Resources is still in its early stages, raising questions about the company's ability to revitalize amidst industry challenges and stagnant core product growth [3] - The reliance on non-recurring gains for profit growth raises concerns about sustainability, as deep-rooted issues such as high accounts receivable, weakened cash flow, and sluggish core business growth have emerged [3]